Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 12/20 | 0.60 |
| ▸ | DRD2 | P14416 | 10/20 | 0.60 |
| ▸ | HTR2A | P28223 | 9/20 | 0.60 |
| ▸ | HTR2C | P28335 | 7/20 | 0.60 |
| ▸ | HTR1A | P08908 | 7/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946571 | 0.90 | DRD2 (0.62) | DRD3DRD2HTR2AHTR2CHTR1A | |
| SCHEMBL8475004 | 0.89 | DRD3 (0.62) | DRD3DRD2HTR2AHTR2CHTR1A | |
| SCHEMBL12946331 | 0.89 | DRD3 (0.64) | DRD3DRD2HTR2AHTR2CHTR1A | |
| SCHEMBL8474519 | 0.87 | USP2 (0.50) | DRD3DRD2HTR2AHTR2CHTR1A | |
| SCHEMBL12946337 | 0.86 | DRD3 (0.61) | DRD3DRD2HTR2AHTR2CHTR1A | |
| SCHEMBL12946323 | 0.86 | DRD2 (0.64) | DRD3DRD2HTR2AHTR2CHTR1A | |
| SCHEMBL12946335 | 0.86 | DRD3 (0.57) | DRD3DRD2HTR2AHTR2CHTR1A | |
| SCHEMBL990005 | 0.86 | DRD3 (0.52) | DRD3DRD2HTR2AHTR2CHTR1A | |
| SCHEMBL8475407 | 0.85 | SLC6A4 (0.56) | DRD3DRD2HTR2AHTR2CDRD4 | |
| SCHEMBL4553502 | 0.85 | DRD3 (0.49) | DRD3DRD2HTR2AHTR2CHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875617-B2 | N-[4-(2-methoxyphenyl)piperazin-1-yl)butyl]-3,4-dihydro-6-fluoro-2-naphthamide for treating neuropsychological disorder selected from Parkinson's disease, schizophrenia and depression; partial agonists or antagonists of the dopamine D3 receptor | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-01-25 | — | — | US | disclosed |
| US-20090124630-A1 | 3, 4-DIHYDRO-2-NAPHTHAMIDE DERIVATIVES AS SELECTIVE DOPAMINE D3 LIGANDS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-05-14 | — | — | US | disclosed |
| EP-1683790-A1 | 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124630-A1 | 3, 4-DIHYDRO-2-NAPHTHAMIDE DERIVATIVES AS SELECTIVE DOPAMINE D3 LIGANDS | DRD3, SLC6A3, DRD2 | DRD3 1/4885DRD2 3/4885HTR2A 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.